305 related articles for article (PubMed ID: 8639800)
1. Bispecific antibody-mediated immunotherapy of the BCL1 lymphoma: increased efficacy with multiple injections and CD28-induced costimulation.
Demanet C; Brissinck J; De Jonge J; Thielemans K
Blood; 1996 May; 87(10):4390-8. PubMed ID: 8639800
[TBL] [Abstract][Full Text] [Related]
2. In vivo studies using bispecific antibodies (anti-CD3 x anti-idiotype) and CD28-induced costimulation in the BCL1 lymphoma.
Demanet C; Brissinck J; De Jonge J; Thielemans K
J Hematother; 1995 Oct; 4(5):363-8. PubMed ID: 8581370
[TBL] [Abstract][Full Text] [Related]
3. Bispecific antibodies target operationally tumor-specific antigens in two leukemia relapse models.
Lindhofer H; Menzel H; Günther W; Hültner L; Thierfelder S
Blood; 1996 Dec; 88(12):4651-8. PubMed ID: 8977258
[TBL] [Abstract][Full Text] [Related]
4. Immunotherapy of B-cell lymphoma with CD3x19 bispecific antibodies: costimulation via CD28 prevents "veto" apoptosis of antibody-targeted cytotoxic T cells.
Daniel PT; Kroidl A; Kopp J; Sturm I; Moldenhauer G; Dörken B; Pezzutto A
Blood; 1998 Dec; 92(12):4750-7. PubMed ID: 9845541
[TBL] [Abstract][Full Text] [Related]
5. Performance of CD3xCD19 bispecific monoclonal antibodies in B cell malignancy.
Haagen IA
Leuk Lymphoma; 1995 Nov; 19(5-6):381-93. PubMed ID: 8590837
[TBL] [Abstract][Full Text] [Related]
6. Locoregional treatment of low-grade B-cell lymphoma with CD3xCD19 bispecific antibodies and CD28 costimulation. II. Assessment of cellular immune responses.
Manzke O; Tesch H; Lorenzen J; Diehl V; Bohlen H
Int J Cancer; 2001 Feb; 91(4):516-22. PubMed ID: 11251975
[TBL] [Abstract][Full Text] [Related]
7. Clinical experience with CD3 x CD19 bispecific antibodies in patients with B cell malignancies.
De Gast GC; Van Houten AA; Haagen IA; Klein S; De Weger RA; Van Dijk A; Phillips J; Clark M; Bast BJ
J Hematother; 1995 Oct; 4(5):433-7. PubMed ID: 8581381
[TBL] [Abstract][Full Text] [Related]
8. MUC1-specific targeting immunotherapy with bispecific antibodies: inhibition of xenografted human bile duct carcinoma growth.
Katayose Y; Kudo T; Suzuki M; Shinoda M; Saijyo S; Sakurai N; Saeki H; Fukuhara K; Imai K; Matsuno S
Cancer Res; 1996 Sep; 56(18):4205-12. PubMed ID: 8797593
[TBL] [Abstract][Full Text] [Related]
9. Role of T-cell subsets in the bispecific antibody (anti-idiotype x anti-CD3) treatment of the BCL1 lymphoma.
Demanet C; Brissinck J; Leo O; Moser M; Thielemans K
Cancer Res; 1994 Jun; 54(11):2973-8. PubMed ID: 8187084
[TBL] [Abstract][Full Text] [Related]
10. Specific activation of resting T cells against CA19-9+ tumor cells by an anti-CD3/CA19-9 bispecific antibody in combination with a costimulatory anti-CD28 antibody.
Hombach A; Tillmann T; Jensen M; Heuser C; Sircar R; Diehl V; Kruis W; Pohl C
J Immunother; 1997 Sep; 20(5):325-33. PubMed ID: 9336739
[TBL] [Abstract][Full Text] [Related]
11. In vivo retargeting of T cell effector function by recombinant bispecific single chain Fv (anti-CD3 x anti-idiotype) induces long-term survival in the murine BCL1 lymphoma model.
De Jonge J; Heirman C; de Veerman M; Van Meirvenne S; Moser M; Leo O; Thielemans K
J Immunol; 1998 Aug; 161(3):1454-61. PubMed ID: 9686611
[TBL] [Abstract][Full Text] [Related]
12. Bispecific antibody treatment of murine B cell lymphoma.
De Jonge J; Heirman C; De Veerman M; Van Meirvenne S; Demanet C; Brissinck J; Thielemens K
Cancer Immunol Immunother; 1997; 45(3-4):162-5. PubMed ID: 9435864
[TBL] [Abstract][Full Text] [Related]
13. Locoregional treatment of low-grade B-cell lymphoma with CD3xCD19 bispecific antibodies and CD28 costimulation. I. Clinical phase I evaluation.
Manzke O; Tesch H; Borchmann P; Wolf J; Lackner K; Gossmann A; Diehl V; Bohlen H
Int J Cancer; 2001 Feb; 91(4):508-15. PubMed ID: 11251974
[TBL] [Abstract][Full Text] [Related]
14. Activation of T cell cytotoxicity against autologous common acute lymphoblastic leukemia (cALL) blasts by CD3xCD19 bispecific antibody.
Csóka M; Strauss G; Debatin KM; Moldenhauer G
Leukemia; 1996 Nov; 10(11):1765-72. PubMed ID: 8892680
[TBL] [Abstract][Full Text] [Related]
15. Bispecific Ab therapy of B-cell lymphoma: target cell specificity of antibody derivatives appears critical in determining therapeutic outcome.
Honeychurch J; Cruise A; Tutt AL; Glennie MJ
Cancer Immunol Immunother; 1997; 45(3-4):171-3. PubMed ID: 9435866
[TBL] [Abstract][Full Text] [Related]
16. CD3-CD28 costimulation as a means to avoiding T cell preactivation in bispecific monoclonal antibody-based treatment of ovarian carcinoma.
Mazzoni A; Mezzanzanica D; Jung G; Wolf H; Colnaghi MI; Canevari S
Cancer Res; 1996 Dec; 56(23):5443-9. PubMed ID: 8968099
[TBL] [Abstract][Full Text] [Related]
17. Specific and effective targeting cancer immunotherapy with a combination of three bispecific antibodies.
Kodama H; Suzuki M; Katayose Y; Shinoda M; Sakurai N; Takemura S; Yoshida H; Saeki H; Asano R; Ichiyama M; Imai K; Hinoda Y; Matsuno S; Kudo T
Immunol Lett; 2002 Apr; 81(2):99-106. PubMed ID: 11852114
[TBL] [Abstract][Full Text] [Related]
18. Treatment of mice bearing BCL1 lymphoma with bispecific antibodies.
Brissinck J; Demanet C; Moser M; Leo O; Thielemans K
J Immunol; 1991 Dec; 147(11):4019-26. PubMed ID: 1940384
[TBL] [Abstract][Full Text] [Related]
19. Treatment of heterotransplanted Hodgkin's tumors in SCID mice by a combination of human NK or T cells and bispecific antibodies.
Renner C; Pfreundschuh M
J Hematother; 1995 Oct; 4(5):447-51. PubMed ID: 8581383
[TBL] [Abstract][Full Text] [Related]
20. Treatment of murine B cell lymphoma with bispecific monoclonal antibodies (anti-idiotype x anti-CD3).
Demanet C; Brissinck J; Van Mechelen M; Leo O; Thielemans K
J Immunol; 1991 Aug; 147(3):1091-7. PubMed ID: 1830596
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
